WATERS CORPORATION |
Market Closed -
Other stock markets
|
After market 21:00:02 | |||
| 280.6 EUR | -0.46% |
|
282.3 | +0.61% |
| 05-29 | Waters Insider Bought Shares Worth $332,900, According to a Recent SEC Filing | MT |
| 05-22 | Deutsche Bank Adjusts Waters Price Target to $330 From $304 | MT |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- With an expected P/E ratio at 28.69 and 25.22 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -6.47% | 18.38B | - | ||
| +7.32% | 217B | B | ||
| +13.83% | 194B | B- | ||
| +20.48% | 143B | B- | ||
| +31.33% | 111B | A- | ||
| +3.08% | 64.3B | A- | ||
| +14.64% | 52.94B | B+ | ||
| +2.72% | 49.53B | B+ | ||
| -5.88% | 38.31B | A | ||
| +0.25% | 35.22B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- WAT Stock
- WAZ Stock
- Ratings Waters Corporation